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Population-Based Estimates of Survival Benefit Associated
with Combined Modality Therapy in Elderly Patients with
Locally Advanced Non-small Cell Lung Cancer
Amy J. Davidoff, PhD, MS,*† James F. Gardner, MS,† Brian Seal, PhD,‡
and Martin J. Edelman, MD*
Purpose: Combined modality therapy (CMT; radiation and chemo-
therapy) is indicated for fit, elderly patients with inoperable, locally
advanced non-small cell lung cancer. We used population level data
to examine effects of CMT on survival.
Methods: Medicare patients who are 66 years or older with locally
advanced non-small cell lung cancer (stages IIIA and IIIB without
pleural effusion) from 1997 to 2002 were identified in Surveillance
Epidemiology and End Results-Medicare. Detailed insurance claims
were used to characterize treatment modality (none, chemotherapy
only, radiotherapy only [XRT-ONLY], or CMT). CMT was further
categorized as sequential (CMT-SEQ), or concurrent chemoradia-
tion alone (CMT-ONLY), with induction (CMT-IND), or with
consolidation chemotherapy (CMT-CON). Nonparametric models
estimated survival effects of treatment regimens, controlling for
patient characteristics, including claims-based indicators of perfor-
mance status. Propensity score analysis adjusted for treatment se-
lection.
Results: Of the 6325 patients, 66% received therapy, with 41%
(N  1745) receiving XRT-ONLY and 45% (N  1909) receiving
CMT (12.5% CMT-SEQ, 35.3% CMT-ONLY, 11.3% CMT-IND,
and 20.3% with CMT-CON). CMT had a survival benefit relative to
XRT-ONLY (hazard ratio: 0.782, 95% confidence interval: 0.750–
0.816; additional 4.4 months median survival; adjusted 10.7% in-
crease in 1-year survival). Relative to CMT-SEQ, concurrent CMT-
ONLY was associated with an increased mortality risk, whereas
CMT-IND regimens provided a survival benefit (hazard ratio: 0.731,
95% confidence interval: 0.600–0.891; additional 3.8 months; and
adjusted 14.4% increase in 1-year survival).
Conclusion: Survival benefits associated with CMT in clinical trials
can extend to the elderly in routine care settings. CMT-ONLY is
associated with the greatest mortality risk, suggesting that more
gradual strategies (CMT-IND) may be more appropriate for the
elderly population.
Key Words: SEER, Lung cancer, Geriatric, Performance status.
(J Thorac Oncol. 2011;6: 934–941)
Approximately 30,000 to 40,000 patients with locally ad-vanced non-small cell lung cancer (LANSCLC) are di-
agnosed annually in the United States, and approximately two
thirds are aged 65 years or older.1 Until 1990, radiation
therapy was considered as the appropriate management for
most patients with inoperable disease. Several trials in the
early 1990s demonstrated that platinum-based chemotherapy
followed by radiation was more effective than radiation
alone.2,3 Subsequent studies demonstrated the superiority of
concurrent chemotherapy and radiation compared with se-
quential treatment.4–6 Current treatment recommendations
include both sequential and concurrent chemoradiation. Re-
cently completed trials have examined the survival benefits of
induction or consolidation chemotherapy, relative to concur-
rent chemoradiation alone.7–12
Clinical trials tend to exclude patients who are older
than 70 years and/or have diminished performance status
(PS). As a result, there is relatively little information con-
cerning outcomes for patients diagnosed with LANSCLC
with these characteristics, or more generally, outside of the
clinical trial setting. Several studies have examined treatment
patterns, finding that patients with NSCLC commonly do not
receive recommended therapy,13–15 but no published popula-
tion-based studies have examined the effects of combined
modality therapy (CMT) on survival in elderly patients. This
population-based study fills that evidence gap. We character-
ized treatment at two levels of complexity, first determining
whether patients received treatment and the modalities re-
ceived as part of any initial treatment. Among patients re-
ceiving CMT, we characterized the sequence and timing of
modalities. A common concern with observational data is the
potential for indication bias, where unobserved differences in
health status, including PS, determine treatment and indepen-
dently affect survival. In this study, we not only control for
health status using standard measures of comorbidity but also
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include indicators associated with poor PS, which we expect
to further reduce indication bias. Finally, propensity score
analysis was used to reduce confounding by characteristics
that are determinants of both treatment and survival.
PATIENTS AND METHODS
Data Source and Patient Cohort
Patients were identified from the National Cancer In-
stitute’s Surveillance Epidemiology and End Results (SEER)
database. SEER aggregates data from 16 regional cancer
registries, including information on the cancer site, stage,
histology, diagnosis date, initial treatment, and date and cause
of death as well as selected demographic characteristics. For
Medicare beneficiaries, SEER data are matched to Medicare
enrollment and claims files. Census tract level measures of
income, education, and racial composition supplement the
demographic information. Medicare Parts A and B claims
data provide detailed service level information for inpatient,
outpatient, hospital, physician, durable medical equipment,
skilled nursing facility, and other care.16
The sample included incident cases of LANSCLC
(American Joint Commission on Cancer stages IIIA and IIIB
without pleural effusion) between 1997 and 2002, among
patients older than 65 years. We used extent of disease and
nodal status to assign substages.17 Staging information is
reported to the SEER registries, but there is no information on
modalities used for staging. Patients were excluded if they
had more than one NSCLC primary; had incomplete infor-
mation concerning dates of diagnosis or death; or had any
period without Medicare Parts A and B or with Health
Maintenance Organization enrollment during the 12 months
before, or any time after diagnosis. This latter exclusion was
necessary to ensure completeness of Medicare claims re-
cords. To focus on management of inoperable disease, we
excluded 24% of patients with surgical lung resection.
Characterization of Treatments
Patients were categorized by whether any treatment
(radiotherapy or chemotherapy) was initiated within 90 days
of diagnosis, to capture therapy with potential curative ben-
efit. We categorized those receiving treatment based on
modality received (radiotherapy only [XRT-ONLY], chemo-
therapy only [CH-ONLY], or CMT). Within CMT, we iden-
tified four distinct patterns with respect to sequencing and
timing of the modalities: (a) sequential, with chemotherapy
followed by radiotherapy (CMT-SEQ); (b) concurrent,
chemoradiation only (CMT-ONLY); (c) induction chemo-
therapy followed by concurrent chemoradiation (CMT-IND);
and (d) concurrent chemoradiation followed by consolidation
chemotherapy (CMT-CON). Mixed patterns of treatment
were grouped into an “other” category. Table 1 presents the
operational definitions used to distinguish treatment groups.
Chemotherapy use was captured based on the presence
of HealthCare Common Procedure Codes and National Drug
Codes for specific agents in outpatient, provider, or durable
medical equipment claims; we did not capture information
from chemotherapy administration claims that were not ac-
companied by a claim for a specific agent. We documented
use of platinum agents (carboplatin or cisplatin), taxanes
(paclitaxel and docetaxel), gemcitabine, vinorelbine, and eto-
poside. When chemotherapy was used, treatment patterns
were measured relative to first-line therapy. We measured
first-line chemotherapy starting with the first claim after
the diagnosis date and including all chemotherapy agents
for which there were claims during the next 29 days.
First-line chemotherapy ended when there was more than
45-day period with no claims for any first-line agents or if
a new chemotherapy agent indicated a switch to second-
line therapy.
Patient Characteristics
Multivariate survival models controlled for diagnosis
age, race, sex, marital status, enrollment at any time in
Medicaid or Medicare Savings Programs in the year before
diagnosis, urban residence, and quartiles for census tract level
measures of median household income. Health status was
measured using a modification of the Charlson Comorbidity
Index (CCI).18,19 The CCI is a weighted count of 19 condition
indicators, measured during the 12 months before the diag-
nosis date to capture baseline comorbidities. The health status
measures also included claims-based indicators specifically
TABLE 1. Measurement of Treatment Modalities
Treatment Category Operational Definition
No treatment within 90 d No XRT or chemotherapy claims within
90 d of diagnosis
Radiation therapy only
(XRT-ONLY)
Radiation therapy claims within 90 d, but
no chemotherapy claims during period
Chemotherapy only
(CH-ONLY)
Chemotherapy claims within 90 d of
diagnosis, but no radiation therapy
claims during period, nor within 45 d of
end of first-line chemotherapy
Combined modality
therapy (CMT)
Claim for chemotherapy within 90 d and
claim for radiation therapy within 90 d
from diagnosis or 45 d from end of
first-line chemotherapy
Sequential chemotherapy—
radiation therapy
(CMT-SEQ)
Claim for chemotherapy within 90 d
followed by first claim for radiation
therapy within 8–45 d of end of first-
line chemotherapy
Concurrent chemotherapy-
radiation therapy
Claim for chemotherapy within 90 d of
diagnosis and claim for radiation
therapy within 14 d of first-
chemotherapy claim
Concurrent only (CMT-
ONLY)
Concurrent chemotherapy and radiation
therapy; no second-line chemotherapy
initiated within 45 d after end of first-
line chemotherapy
Concurrent with induction
therapy (CMT-IND)
Concurrent chemotherapy and radiation
therapy, but chemotherapy start
precedes first radiation claim by at least
14 d but not longer than 90 d
Concurrent with
consolidation
(CMT-CON)
Concurrent chemotherapy-radiation
therapy followed by period of
chemotherapy starting within 45 d of
end of radiation. Chemotherapy agent
may be same as first line or different
agents may be used
XRT, radiotherapy.
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designed to capture patients with poor PS.20 These indicators
include hospitalization, skilled nursing facility stay, long-
term care facility stay, home health agency services, oxygen
and respiratory therapy services, and claims for walkers,
wheelchairs, and related equipment. These indicators were
measured during the same time period as the CCI, and
information was summarized in count variables.
Statistical Methods
Survival was calculated based on the period between
diagnosis or initial treatment, and either death or censoring.
Diagnosis date is reported in SEER based on month and year.
We assigned the diagnosis date to the first day of the diag-
nosis month. We report “all cause” mortality because it
captures the full effects of the disease. Patient records were
censored if they were alive at the end of the period (Decem-
ber 2005). The first patients were diagnosed in 1997 and thus
had between 3 and 8 years of potential follow-up.
We examined the association between treatment and
survival in two stages: the effect of treatment modality on
treated patients and the effect of modality sequence for CMT
recipients. For the former comparison, we measured survival
from the date of diagnosis. For the latter, we measured
survival from initiation of treatment. We estimated Kaplan-
Meier survival functions to calculate median survival and
tested for equality across treatment groups using a log-rank
test. We estimated logit and nonparametric (Cox) survival
models to examine the effect of treatment modality on sur-
vival, controlling for patient demographic, health status, and
tumor characteristics.21,22 We tested the nonparametric mod-
els for the proportionality assumptions using Schoenfeld
residuals and added interaction terms between treatment and
time to adjust for nonproportional hazards.
We used propensity score analysis to balance the char-
acteristics of the treatment groups. There are several ways to
apply propensity scores. We used inverse propensity score
weighting because it makes use of the full sample of obser-
vations and, thus, increases generalizability.23 The propensity
score weights assigned were the inverse of the predicted
probability of being in the observed treatment group.
We present selected estimation results from nonpara-
metric survival models, with propensity score adjustment but
without adjustment for nonproportionality.24 Sensitivity anal-
yses (with propensity adjustment and with adjustment for
nonproportionality) are summarized in Supplemental Digital
Content documents 3 and 4 (http://links.lww.com/JTO/A65
and http://links.lww.com/JTO/A66). All analyses were con-
ducted using Stata version 9 (StataCorp, College Station,
TX). The study was approved by the University of Maryland
Baltimore Institutional Review Board.
RESULTS
Patterns of Nonsurgical Treatment for Patients
with LANSCLC
The final sample size was 6325. Therapy was initiated
within 90 days of diagnosis for 4222 (66.8%) elderly patients
(Table 2), with 427 (6.8%) initiating cancer therapy after 90
days, and 1676 (26.5%) not receiving any cancer directed
TABLE 2. Patterns of Chemotherapy and Radiation Treatment in Elderly Patients with Locally Advanced Non-small Cell Lung
Cancer
Treatment Category
Sample Size
Time to Initiation
of Chemotherapy
or Radiation
Therapy (d)
Length First-Line
Chemotherapy (d) First-Line
Platinum-Based
Doublet (%)
Received
Subsequent
Chemotherapy (%)N Percentage Mean SE Mean SE
Any chemotherapy or radiation therapy
treatment
None 1676 26.5
Yes, not within 90 d 427 6.8
Yes, within 90 d of diagnosis 4222 66.8
Treatment modality, conditional on
treatment within 90 d
Radiation therapy only (XRT-ONLY) 1745 41.3 36.3 0.1
Chemotherapy only (CH-ONLY) 568 13.5 45.2 0.8 72.6 3.4 76.1 46.3
Combined modality therapy (CMT) 1909 45.2 50.7 0.6 63.3 1.2 86.3 32.8
Sequencing of XRT and chemotherapy,
conditional on CMT
Sequential (CMT-SEQ) 239 12.5 46.9 1.2 55.6 2.5 90.4 35.6
Concurrent Only (CMT-ONLY) 674 35.3 45.9 0.7 36.2 0.9 85.8 24.0
Chemoinduction, concurrent
(CMT-IND)
215 11.3 42.9 1.1 94.7 3.2 94.4 42.3
Concurrent with consolidation
(CMT-CON)
387 20.3 42.2 0.9 104.4 3.1 89.7 43.2
Source: Surveillance, Epidemiology, and End Results (SEER)-Medicare, 1997–2002.
SE, standard error.
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therapy after diagnosis. Among those receiving therapy,
41.3% received XRT-ONLY, 13.5% CH-ONLY, and 45.2%
received CMT. Among the latter group, the most common
pattern was CMT-ONLY (35.3%). Other patients received
CMT-SEQ (12.5%), CMT-IND (11.3%), and CMT-CON
(20.3%). Time to initiation of chemotherapy was similar
across groups, ranging from 42.2 to 46.9 days, whereas
treatment was initiated earlier for the XRT-ONLY group
(36.3 days). Mean length of first-line chemotherapy was
longest for the CMT-IND and CMT-CON subgroups at 94.7
and 104.4 days, respectively, and shortest for the CMT-
ONLY group (36.2 days). The proportion receiving platinum-
based doublet regimens ranged from 85.8 to 94.4% among
the CMT groups but was lower (76.1%) among patients
receiving CMT-ONLY. Demographic and disease character-
istics of the sample overall, by receipt of any treatment, and
by treatment modality are presented in Supplemental Digital
Content 1 (http://links.lww.com/JTO/A67). Patients not re-
ceiving any treatment and those receiving XRT-ONLY were
disproportionately older, African American, not currently
married, received Medicaid, and had greater comorbidity and
more indicators of poor PS. Estimated treatment propensity
models are included in Supplemental Digital Content 2
(http://links.lww.com/JTO/A68).
Effects of Treatment on Survival
Median survival was 8.4 months overall (95% confi-
dence interval [CI]: 8.1–8.7), with 36% 1-year survival and
15.1% 2-year survival (Table 3). Excluding those with sur-
vival less than 30 days, median survival was 9.6 versus 6.9
months (95% CI: 9.3–10.0 versus 6.4–7.4) for treated com-
pared with untreated patients and 12.0 versus 7.6 months
TABLE 3. Median, Mean, and 1-Year and 2-Year Survival Effects of Treatment for Locally Advanced Non-small Cell Lung
Cancer
Kaplan-Meier Survival (mo)
Discrete Survival
Adjusted Effects of
Treatment on Discrete
Survival
N Median 95% CI
One Year
(%)
Two Years
(%)
One Year
(%)
Two Years
(%)
All patients, no minimum survival 6323 8.4 8.1 — 8.7 36.0 15.1
All patients, 30 d minimum survival 6089 8.8 8.6 — 9.1 37.4 15.7
Any chemotherapy or radiation therapy
initiated within 90 d of diagnosis
None 1918 6.9 6.4 — 7.4 31.0 13.0
Yes 4171 9.6 9.3 — 10.0 40.3 17.0 7.8a 2.8a
Treatment modality, conditional on
treatment within 90 d
XRT only 1852 7.6 7.2 — 8.1 32.3 11.8
Chemotherapy only 630 10.4 9.4 — 11.5 44.4 16.8 5.8b 0.5
Combined Modality 1995 12.0 11.4 — 12.5 49.2 23.0 10.7a 6.1a
Sequencing of XRT and chemotherapy,
conditional on CMT—time from
diagnosis
Sequential 239 11.5 10.0 — 13.0 47.9 21.9
Concurrent only 673 9.5 8.8 — 10.3 40.5 18.0 4.3 2.0
Chemotherapy induction, concurrent 215 15.2 13.8 — 17.2 63.5 30.8 16.6a 8.8b
Concurrent with consolidation 387 13.5 12.1 — 15.3 55.0 27.4 8.4b 6.5c
Sequencing/overlap of XRT and
chemotherapy, conditional on
CMT—time from treatment
initiation
Sequential 239 9.7 8.4 — 11.5 42.7 20.9
Concurrent only 652 8.4 7.6 — 9.5 36.6 17.5 4.4 2.2
Chemotherapy induction, concurrent 215 13.6 12.5 — 16.0 57.4 29.4 14.4b 7.3
Concurrent with consolidation 386 12.4 10.6 — 14.1 50.0 26.1 8.4c 5.1c
Kaplan-Meier survival functions significantly different for treated versus untreated, by treatment modality, and by sequencing/timing of CMT, p  0.0001. Percent with 1- and
2-yr survival, significantly different across all categories, p  0.001. Adjusted effects of treatment on discrete survival are computed as the difference in predicted probabilities
associated with different treatment regimens. Models controlled for patient demographics (age, race, sex, marital status, area income, Medicaid/MSP, and urban-rural location), health
status (CCI, poor PS indicators), tumor substage, histology, and behavior.
Source: SEER-Medicare 1997–2005.
a Estimated coefficients significant at p  0.01.
b Estimated coefficients significant at p  0.05.
c Estimated coefficients significant at p  0.10.
XRT, radiotherapy; CMT, combined modality therapy; MSP, Medicare Savings Programs; SEER, Surveillance, Epidemiology and End Results; CCI, Charlson Comorbidity
Index; PS, performance status.
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(95% CI: 11.4–12.5 versus 7.2–8.1) for patients receiving
CMT relative to XRT-ONLY. Among those receiving CMT,
survival was 13.6 versus 9.7 months (95% CI: 12.5–16.0
versus 8.4–11.5) for CMT-IND, compared with CMT-SEQ.
The difference was even greater relative to CMT-ONLY.
Adjusted 1-year and 2-year survival rates were consistent
with these patterns. For example, patients receiving CMT
were 10.7 (p  0.01) [6.1, p  0.01] percentage points more
likely to achieve a 1 [2] year survival, compared with patients
receiving XRT-ONLY.
Estimates of the effects of treatment modality on mor-
tality, adjusted for patient and tumor characteristics, indicate
a significant survival advantage to CMT, but at most a small
effect of CH-ONLY, relative to XRT-ONLY. Table 4 pres-
ents estimated hazard ratios (HRs) for the preferred propen-
sity score adjusted model. The estimated HR for CMT was
0.782 (95% CI: 0.750–0.816). Independent of treatment,
increased age, being male, African American, living in a
smaller urban area, squamous histology, poorly defined or
unknown tumor grade, high baseline comorbidity, and poor
PS are associated with higher risk of mortality. Being mar-
ried, moderate income (second relative to lowest quartile),
stage IIIA, and other histology reduced mortality risk. Esti-
mated effects for the subset of patients receiving platinum-
based regimens were similar to the overall estimates (results
not shown).
When we examined the survival effects among the
CMT subgroups (Table 5), adjusted for patient and tumor
characteristics, we find that relative to CMT-SEQ, CMT-
ONLY is associated with increased mortality risk (HR: 1.159,
95% CI: 1.074–1.251), whereas CMT-IND and CMT-CON
confer a survival benefit with HRs of 0.755 (95% CI: 0.699–
0.816) and 0.849 (95% CI: 0.787–0.917), respectively. In
addition, increasing age, male, rural residence, increasing
comorbidity burden, and having at least one indicator of poor
PS were all associated with increased mortality risk. Supple-
mental digital contents 3 and 4 provide descriptions and
results for alternative models estimated.
CONCLUSIONS
The results of this population-based study indicate that
CMT provides a significant survival benefit for elderly patients
with LANSCLC when used in a routine practice setting. Al-
though clinical trials had demonstrated the benefits of CMT for
younger patients approximately two decades ago, the benefits of
CMT in the elderly had been the subject of considerable con-
troversy. For example, secondary analysis of a Radiation Ther-
apy Oncology Group (RTOG) study demonstrated inferior out-
comes of chemoradiation for the elderly (age 70 years) and
those with poorer PS.25 Those findings may have reflected a
higher level of treatment toxicity in that era associated with both
chemotherapy agents and radiation fields used. In contrast,
subset analyses of several trials have found benefits associated
with CMT for the elderly. These include a study by Langer et
al.26 that evaluated an elderly subset from a trial comparing
CMT-SEQ with CMT-ONLY (RTOG 9410) and a study by
Jeremic and Shibamoto27 comparing effects of hyperfractionated
radiotherapy with or without chemotherapy. Socinski et al.28
examined results from five Cancer and Leukemia Cooperative
Group B trials and concluded that age was not an independent
predictive factor of outcome. The results of this study are
consistent with the positive results identified in these latter
TABLE 4. Effect of Treatment Modality on Survival:
Chemotherapy Only, Combined Modality Therapy
Compared with Radiotherapy Only (Model in Inverse
Propensity Score Weighted, No Time Interactions)
Hazard
Ratio
95% Confidence
Interval
Treatment (reference is XRT only)
CH-ONLY 0.958 0.918 0.999a
CMT 0.782 0.750 0.816b
Age (reference is age 66–69 yr)
70–74 0.978 0.928 1.030
75–79 1.095 1.038 1.154b
80–84 1.235 1.163 1.311b
85 1.699 1.573 1.835b
Race (reference is white)
African American 1.087 1.021 1.158b
Other 0.780 0.715 0.850b
Male 1.157 1.113 1.203b
Married 0.953 0.917 0.991a
Medicaid/MSP 1.009 0.957 1.065
Income Quartile (reference is
“Lowest”)
Second 0.879 0.836 0.925b
Third 0.970 0.919 1.024
Highest 0.960 0.908 1.016
Urbanicity (reference is large metro,
metro)
Urban, non-MSA 1.143 1.066 1.225b
Rural 1.007 0.945 1.074
Substage 3A 0.908 0.876 0.940b
Histology (reference is
adenocarcinoma)
Squamous cell 1.065 1.018 1.115b
Large cell 1.045 0.973 1.124
Other histology 0.903 0.859 0.949b
Grade (reference is well, moderately
well differentiated)
Fair/poor 1.161 1.100 1.226b
Unknown 1.092 1.035 1.151b
Charlson Comorbidity Index
(reference is CCI  0)
CCI  1 1.040 0.997 1.086c
CCI  2 1.024 0.963 1.088
CCI  3 1.104 1.027 1.188b
Poor PS indicator count (reference is
“none”)
One 1.229 1.171 1.291b
Two or more 0.977 0.914 1.043
Source: SEER-Medicare 1997–2002.
a Estimated hazard ratios significant at p  0.05.
b Estimated hazard ratios significant at p  0.01.
c Estimated hazard ratios significant at p  0.10.
CMT, combined modality therapy; MSP, Medicare Savings Programs; CCI, Charl-
son Comorbidity Index; PS, performance status; SEER, Surveillance, Epidemiology and
End Results.
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studies, while extending the findings to a more heterogeneous
population. Although examining patterns of treatment was not a
particular focus of this study, it is worth noting that use of CMT
among the elderly likely increased after publication of Socinski
et al. Future research is indicated to capture trends in treatment
over time and by age subgroup, and to determine whether there
has been an overall improvement in patient survival.
Despite the relative survival benefit associated with
CMT in this analysis, the absolute survival duration among
this Medicare elderly population is shorter than that reported
in many clinical trials, regardless of treatment regimen7,9–12
(see Supplemental Digital Content 5, which summarizes
results from selected trials, http://links.lww.com/JTO/A69).
This difference may reflect the higher comorbidity or worse
PS burden experienced by the elderly population, which may
reduce treatment tolerance, increase adverse events, and re-
duce dosing or duration of treatment. These findings are
consistent with findings from a recent population-based study
that relatively few patients with LANSCLC would meet age
or PS restrictions for concurrent therapy, let alone clinical
trial participation.29
The survival benefit associated with CMT seems to
vary depending on the sequencing and timing of the compo-
nent therapies. In contrast to the results from prospective
clinical trials, which have documented the benefit of concur-
rent relative to CMT-SEQ and questioned the use of CMT-IND
and/or CMT-CON, we find that CMT-ONLY is associated
with increased mortality risk. We also find that CMT-IND
reduces mortality risk, whereas results are mixed concerning
the benefit of CMT-CON. The question of whether a CMT-
IND regimen improves survival over CMT-ONLY was ad-
dressed in Cancer and Leukemia Cooperative Group B
39801. Overall results were negative, as were results from a
subanalysis focused on high-risk groups (defined as having
2 risk factors: age 70 years, hemoglobin 13 g/dl, PS of
1 versus 0, and weight loss 5).30 Nevertheless, the stratified
analysis may have suffered from limited statistical power.
Again, the apparent inconsistency between clinical trial and
population-based results may be due to an even greater
burden of comorbidity and poor PS in this study compared
with the high-risk group within the clinical trial. For the
population in this study, induction chemotherapy may have
reduced disease burden and improved PS to allow for con-
current therapy. This strategy may have allowed early iden-
tification of patients who are more susceptible to toxicity and
thereby enriched the population for those likely to tolerate
therapy. Given various possible interpretations of these re-
sults, they should be seen as hypothesis generating.
This study is subject to the usual limitations associated
with analysis of administrative enrollment and claims data.
Although SEER-Medicare provides essential information on
cancer-specific stage and histology, and timing and cause of
death, measurement of health status, and characterization of
treatments and intermediate outcomes such as toxicities,
adverse events, and disease progression can only be gleaned
from diagnoses and procedures reported through the Medi-
care claims.31 In our study, we enhanced measurement ap-
proaches in two key ways. First, we included indicators for
TABLE 5. Effect of Treatment on Survival: Concurrent
Chemoradiation Alone, with Induction, or with
Consolidation, Relative to Sequential Therapy (Model is
Inverse Propensity Score Weighted, No Time Interactions)
Hazard
Ratio
95% Confidence
Interval
Treatment modality (reference is
CMT-SEQ)
CMT-ONLY 1.159 1.074 1.251a
CMT-IND 0.755 0.699 0.816a
CMT-CON 0.849 0.787 0.917a
Age (reference is age 66–69)
70–74 0.959 0.892 1.030
75–79 1.103 1.021 1.191b
80–84 1.300 1.174 1.440a
85 1.287 1.060 1.562b
Race (reference is white)
African American 1.056 0.951 1.173
Other 0.559 0.444 0.703a
Male 1.182 1.115 1.254a
Married 0.947 0.891 1.006c
Medicaid/MSP 0.934 0.843 1.035
Income quartile (reference is
“Lowest”)
Second 1.092 1.007 1.184b
Third 0.836 0.764 0.914a
Highest 1.060 0.968 1.161
Urbanicity (reference is large
metro, metro)
Urban, non-MSA 0.997 0.891 1.116
Rural 1.100 1.002 1.208b
Substage 3A 0.971 0.918 1.026
Histology (reference is
adenocarcinoma)
Squamous cell 0.947 0.882 1.018
Large cell 0.917 0.825 1.019
Other histology 0.998 0.924 1.078
Grade (reference is well,
moderately well
differentiated)
Fair/poor 1.048 0.963 1.141
Unknown 1.051 0.966 1.143
Charlson Comorbidity Index
(reference is CCI  0)
CCI  1 1.025 0.962 1.094
CCI  2 1.361 1.236 1.499a
CCI  3 1.331 1.169 1.517a
Poor PS indicator count
(reference is “none”)
One 1.131 1.046 1.224a
Two or more 1.042 0.922 1.177
Source: SEER-Medicare 1997–2002.
a Estimated hazard ratios significant at p  0.01.
b Estimated hazard ratios significant at p  0.05.
c Estimated hazard ratios significant at p  0.10.
CMT, combined modality therapy; MSP, Medicare Savings Programs; CCI, Charl-
son Comorbidity Index; PS, performance status; SEER, Surveillance, Epidemiology and
End Results.
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poor PS in both our propensity and survival models. These
indicators were selected based on their association with
difficulty in ambulation20 and in several other studies by this
group have been associated with less aggressive treatment
and with increased mortality risk.20,32,33 These measures do
not capture weight loss, an important prognostic factor for
patients with lung cancer. Although further development of
this approach to capture PS using claims data is underway,34
we believe that these preliminary indicators of poor PS
provide an additional measure of control for health status.
Although it is fairly straightforward to identify any use
of each treatment modality, capturing treatment duration and
timing is more challenging. In this study, we extended pre-
vious approaches by examining the temporal relationships
and overlap in receipt of different modalities. Using dates of
service available in claims and devising algorithms to com-
pare relative timing of different modalities, we were able to
distinguish concurrent from sequential receipt of chemother-
apy and radiation, and to distinguish periods of induction and
CMT-CON from concurrent chemoradiation. Although our
characterization of treatment regimens is somewhat sensitive
to the specific rules used in our algorithm, for example, the
width of the time window used to distinguish concurrent from
sequential treatment, we feel comfortable that our current
measures closely approximate the actual pattern of treatment.
We do acknowledge, however, that for patients who die or
otherwise discontinue therapy shortly after initiating treat-
ment, we are not able to fully discern the intended treatment
regimen, only that portion that we are able to observe. Hence,
when we observe a patient receiving CH-ONLY, we cannot
determine whether the clinician intended a regimen of CH-
ONLY or intended to use CMT-SEQ, but the patient had an
adverse event and terminated treatment. Our use of propen-
sity score analysis is intended to address this type of con-
founding by indication. Nevertheless, we recognize that treat-
ment decisions may be based on health events that are not
easily observed using claims data; hence, there may be
residual bias in our estimates. Use of other methods, such as
instrumental variable analysis, can be used to address indi-
cation bias based on unobservable variables. Nevertheless,
instrumental variable analysis has not been developed for use
within the context of nonparametric survival models. Further
examination of both the effects of complex treatment regi-
mens and instrumental variable analysis is warranted.
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